These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 11206690)

  • 21. Pharmacokinetic evaluation and dosing of subcutaneous testosterone pellets.
    Pastuszak AW; Mittakanti H; Liu JS; Gomez L; Lipshultz LI; Khera M
    J Androl; 2012; 33(5):927-37. PubMed ID: 22403285
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety of a New Subcutaneous Testosterone Enanthate Auto-Injector: Results of a 26-Week Study.
    Gittelman M; Jaffe JS; Kaminetsky JC
    J Sex Med; 2019 Nov; 16(11):1741-1748. PubMed ID: 31551193
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men.
    Dobs AS; Meikle AW; Arver S; Sanders SW; Caramelli KE; Mazer NA
    J Clin Endocrinol Metab; 1999 Oct; 84(10):3469-78. PubMed ID: 10522982
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New testosterone buccal system (Striant) delivers physiological testosterone levels: pharmacokinetics study in hypogonadal men.
    Wang C; Swerdloff R; Kipnes M; Matsumoto AM; Dobs AS; Cunningham G; Katznelson L; Weber TJ; Friedman TC; Snyder P; Levine HL
    J Clin Endocrinol Metab; 2004 Aug; 89(8):3821-9. PubMed ID: 15292312
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transdermal androgen therapy to augment EPO in the treatment of anemia of chronic renal disease.
    Brockenbrough AT; Dittrich MO; Page ST; Smith T; Stivelman JC; Bremner WJ
    Am J Kidney Dis; 2006 Feb; 47(2):251-62. PubMed ID: 16431254
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Natesto™ , a novel testosterone nasal gel, normalizes androgen levels in hypogonadal men.
    Rogol AD; Tkachenko N; Bryson N
    Andrology; 2016 Jan; 4(1):46-54. PubMed ID: 26695758
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transdermal testosterone gel increases serum testosterone levels in hypogonadal men in Taiwan with improvements in sexual function.
    Chiang HS; Hwang TI; Hsui YS; Lin YC; Chen HE; Chen GC; Liao CH
    Int J Impot Res; 2007; 19(4):411-7. PubMed ID: 17538639
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
    Coward RM; Simhan J; Carson CC
    BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetic characteristics, efficacy, and safety of buccal testosterone in hypogonadal males: a pilot study.
    Dobs AS; Hoover DR; Chen MC; Allen R
    J Clin Endocrinol Metab; 1998 Jan; 83(1):33-9. PubMed ID: 9435413
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interrelationships among lipoprotein levels, sex hormones, anthropometric parameters, and age in hypogonadal men treated for 1 year with a permeation-enhanced testosterone transdermal system.
    Dobs AS; Bachorik PS; Arver S; Meikle AW; Sanders SW; Caramelli KE; Mazer NA
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1026-33. PubMed ID: 11238481
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An open-label, phase 2, single centre, randomized, crossover design bioequivalence study of AndroForte 5 testosterone cream and Testogel 1% testosterone gel in hypogonadal men: study LP101.
    Wittert GA; Harrison RW; Buckley MJ; Wlodarczyk J
    Andrology; 2016 Jan; 4(1):41-5. PubMed ID: 26754331
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics and metabolism of a permeation-enhanced testosterone transdermal system in hypogonadal men: influence of application site- -a clinical research center study.
    Meikle AW; Arver S; Dobs AS; Sanders SW; Rajaram L; Mazer NA
    J Clin Endocrinol Metab; 1996 May; 81(5):1832-40. PubMed ID: 8626843
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum LH concentrations in hypogonadal men during transdermal testosterone replacement through scrotal skin: further evidence that ageing enhances testosterone negative feedback. The Testoderm Study Group.
    Winters SJ; Atkinson L
    Clin Endocrinol (Oxf); 1997 Sep; 47(3):317-22. PubMed ID: 9373453
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clomiphene citrate and testosterone gel replacement therapy for male hypogonadism: efficacy and treatment cost.
    Taylor F; Levine L
    J Sex Med; 2010 Jan; 7(1 Pt 1):269-76. PubMed ID: 19694928
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term substitution therapy of hypogonadal men with transscrotal testosterone over 7-10 years.
    Behre HM; von Eckardstein S; Kliesch S; Nieschlag E
    Clin Endocrinol (Oxf); 1999 May; 50(5):629-35. PubMed ID: 10468929
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Testosterone replacement therapy does not promote priapism in hypogonadal men with sickle cell disease: 12-month safety report.
    Morrison BF; Reid M; Madden W; Burnett AL
    Andrology; 2013 Jul; 1(4):576-82. PubMed ID: 23606509
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics and safety of long-acting testosterone undecanoate injections in hypogonadal men: an 84-week phase III clinical trial.
    Wang C; Harnett M; Dobs AS; Swerdloff RS
    J Androl; 2010; 31(5):457-65. PubMed ID: 20133964
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improved sexual function with testosterone replacement therapy in hypogonadal men: real-world data from the Testim Registry in the United States (TRiUS).
    Khera M; Bhattacharya RK; Blick G; Kushner H; Nguyen D; Miner MM
    J Sex Med; 2011 Nov; 8(11):3204-13. PubMed ID: 21834870
    [TBL] [Abstract][Full Text] [Related]  

  • 39. LH and non-SHBG testosterone and estradiol levels during testosterone replacement of hypogonadal men: further evidence that steroid negative feedback increases as men grow older.
    Winters SJ; Wang C;
    J Androl; 2010; 31(3):281-7. PubMed ID: 19959827
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prostate-specific antigen (PSA) concentrations in hypogonadal men during 6 years of transdermal testosterone treatment.
    Raynaud JP; Gardette J; Rollet J; Legros JJ
    BJU Int; 2013 May; 111(6):880-90. PubMed ID: 23294726
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.